The medical ethics professional committee of the China Anti-Cancer Association (CACA) has announced the formation of the China Cancer Clinical Research Medical Ethics Review Mutual Recognition Consortium. This consortium aims to streamline and standardize the ethical review process for clinical research in cancer treatment across China.
The founding members of the consortium include prominent medical institutions such as Beijing Cancer Hospital, Fujian Cancer Hospital, and Fudan University Shanghai Cancer Center, along with 17 other medical entities. They are joined by leading pharmaceutical companies BeiGene, InnoCare, Tigermed, HutchMed, Hengrui Medicine, Roche, Qilu Pharma, Junshi Bio, Xianxiang Pharma, and Johnson & Johnson.- Flcube.com
